IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
Quantum BioPharma's Executive Co-Chair Anthony Durkacz appeared on The BioMedWire Podcast to discuss the company's lead drug candidate Lucid-MS, which is advancing to a Phase 2 trial in multiple sclerosis patients targeting myelin repair. Durkacz also highlighted unbuzzd™, the alcohol-metabolism powder spun out to Unbuzzd Wellness Inc., which is currently going through an IPO process ahead of a planned full marketing launch. Quantum owns approximately 19.48% of Unbuzzd (as of June 30, 2026) and holds a 7% royalty on sales until payments total $250 million, dropping to 3% thereafter.
Key figures
- Royalty rate
- 7% of sales until payments total $250 million, then 3% in perpetuity
- Unbuzzd ownership pct
- 19.48% (as of June 30, 2026)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.